Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

During the first half of 2025, we achieved target enrollment in our ongoing gene therapy clinical trials of TN-201 for MYBPC3-associated HCM and ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Jaipur: SMS Hospital has established a department for treatment of blood-related cancers and other blood disorders. The ...

A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...

LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Wednesday reported a loss of $33.4 million in its second quarter. On a per-share basis, the Lexington, Massachusetts ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Uppsala University Hospital-led investigators report that gene-edited donor islet cells survived 12 weeks inside a man with ...

A combo of cancer drugs letrozole and irinotecan has been identified — via a complex AI-driven study — to reverse memory ...

Key Points Non-GAAP earnings per share reached $0.74, surpassing estimates by $0.03 (non-GAAP), but GAAP revenue of $181.1 million missed expectations and rose 1.7% (GAAP) compared to the second ...

At only 6 months, Gerard and Kaitlin Norton’s daughter Madeline was diagnosed with PKAN, a rare neurodegenerative disorder ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...